The Tmod CAR-T platform uses tumor- and non-tumor-specific elements to spare normal cells while killing tumor cells without sacrificing cytotoxic potency.
A panel of 13 circulating proteins related to the tumor microenvironment may provide prognostic clues to prostate cancer progression.
The UK company expects the pyrophosphorolysis-based technology to have cost and convenience advantages over sequencing-based assays.
The company plans to launch an early access program for its DefineMBC assay in April, followed by a full commercial launch later in the year.
Caring Cross aims to launch a commercial model, in which hospital-based sites can themselves manufacture the CAR T-cell products.
After a promising pilot study, researchers at the University of Helsinki are starting a larger investigation of patients' response to drugs selected via this method.
Sysmex also recently formed a companion diagnostic development partnership with Qiagen, which could help with its efforts in this area.
The companies are collaborating to study breast cancer mutational profiles among Ghanaian women and build local testing and analysis capacity.
The technique, used in noninvasive prenatal testing to detect microduplications or microdeletions, could detect copy number alterations in B-cell lymphoma patients.
The method, called HPV-Seq, detected ctDNA with high sensitivity and specificity, and could help hone precision treatments of HPV-related cancers.